Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Study of Talabostat in Advanced Melanoma

Lead Sponsor:

Point Therapeutics

Conditions:

Melanoma

Skin Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed melanoma that is metastatic (unresectable Stage IV per AJCC 2002)
  • Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins
  • ECOG Performance Status of 0, 1, or 2
  • Expected survival ≥12 weeks
  • Written informed consent

Exclusion

  • More than 1 prior chemotherapy or biotherapy regimen for Stage IV melanoma
  • Radiation therapy to \>50% of the bone marrow. Patients must not have had prior radiotherapy to index lesions unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
  • Clinically significant laboratory abnormalities
  • CNS metastases
  • Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix
  • The need for chronic (i.e., \>7 days) oral or intravenous corticosteroid therapy
  • Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
  • Patients who are within 30 days of chemotherapy, radiation therapy, immunotherapy, or other investigational medication for melanoma. Patients must have recovered from all of the side effects of treatment in order to be enrolled.
  • Pregnant or lactating women.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00083239

Last Update

June 8 2007

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Emory University/Winship Cancer Institute

Atlanta, Georgia, United States, 30322-1013

2

University of Chicago

Chicago, Illinois, United States, 60637

3

University of Michigan

Ann Arbor, Michigan, United States, 48109-0473

4

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States, 03756-0001